The HER2-positive gastric cancer treatment landscape has experienced unprecedented metamorphosis, evolving from a specialized therapeutic niche into a flagship area of targeted cancer medicine. This transformation is fueled by deepened insights into HER2 molecular mechanisms, breakthrough antibody-drug conjugate (ADC) developments, and extensive regulatory recognition across international...